532 related articles for article (PubMed ID: 28508992)
1. Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus.
Buchs C; Dalphin ML; Sanchez S; Perceval M; Coutier L; Mainguy C; Kassaï-Koupaï B; Reix P
Eur J Pediatr; 2017 Jul; 176(7):891-897. PubMed ID: 28508992
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.
Groves HE; Jenkins L; Macfarlane M; Reid A; Lynn F; Shields MD
Pediatr Pulmonol; 2016 Apr; 51(4):379-85. PubMed ID: 26808981
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Bjornson C; Chan P; Li A; Paes B; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007743. PubMed ID: 27439110
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ
Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
Cochrane Database Syst Rev; 2012 Feb; (2):CD007743. PubMed ID: 22336832
[TBL] [Abstract][Full Text] [Related]
7. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
Cochrane Database Syst Rev; 2013 Jun; (6):CD007743. PubMed ID: 23737087
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab and Long-term Outcomes in Cystic Fibrosis.
Fink AK; Graff G; Byington CL; Loeffler DR; Rosenfeld M; Saiman L
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31239289
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha I; McKoy N
Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
Kua KP; Lee SWH
Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
Smyth AR; Walters S
Cochrane Database Syst Rev; 2014 Nov; (11):CD001912. PubMed ID: 25419599
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
Smyth AR; Rosenfeld M
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD001912. PubMed ID: 28417451
[TBL] [Abstract][Full Text] [Related]
15. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis.
Sánchez-Solis M; Gartner S; Bosch-Gimenez V; Garcia-Marcos L
Allergol Immunopathol (Madr); 2015; 43(3):298-303. PubMed ID: 24231153
[TBL] [Abstract][Full Text] [Related]
16. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
Smyth AR; Walters S
Cochrane Database Syst Rev; 2012 Dec; 12():CD001912. PubMed ID: 23235585
[TBL] [Abstract][Full Text] [Related]
18. A post-incorporation study on the use of palivizumab in the Brazilian public health system.
Batista JDL; Ferreira MAP; Xavier CDS; Souza ITA; Cruz LN; Polanczyk CA
Rev Inst Med Trop Sao Paulo; 2021; 63():e5. PubMed ID: 33533808
[TBL] [Abstract][Full Text] [Related]
19. Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children With Cystic Fibrosis.
Metz J; Eber E; Resch B
Pediatr Infect Dis J; 2017 Jun; 36(6):545-548. PubMed ID: 28005688
[TBL] [Abstract][Full Text] [Related]
20. Season is associated with Pseudomonas aeruginosa acquisition in young children with cystic fibrosis.
Psoter KJ; De Roos AJ; Wakefield J; Mayer J; Rosenfeld M
Clin Microbiol Infect; 2013 Nov; 19(11):E483-9. PubMed ID: 23795938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
